UroGen Pharma (URGN) Cash from Operations (2017 - 2026)
UroGen Pharma's (URGN) quarterly Cash from Operations came in at 45316000.0 in Q1 2026, down 7.83% YoY from 49167602.6 in Q1 2025, and down 18.24% on a QoQ basis from 38325000.0 in Q4 2025.
UroGen Pharma (URGN) Cash from Operations (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Cash from Operations data on file, last reported at 45316000.0 in Q1 2026.
- Quarterly Cash from Operations fell 7.83% year-over-year to 45316000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 165736000.0 (down 54.81% YoY) and the FY2025 annual result came in at 162444000.0, down 67.87% from the prior year.
- Cash from Operations slipped to 45316000.0 in Q1 2026, from 38325000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 12996000.0 in Q4 2023 to a low of 45316000.0 in Q1 2026.
- A 5-year average of 27556529.41 and a median of 24199000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations soared 40.25% — and 2025, when it sank 181.41%.
- Tracing URGN's Cash from Operations over 5 years: stood at 21752000.0 in 2022, then soared by 40.25% to 12996000.0 in 2023, then fell by 4.79% to 13619000.0 in 2024, then slumped by 181.41% to 38325000.0 in 2025, then fell by 18.24% to 45316000.0 in 2026.
- The last three Cash from Operations figures came in at 45316000.0 (Q1 2026), 38325000.0 (Q4 2025), and 42270000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -33.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.01 Mn |
| Jun 30, 2026 | -33.01 Mn |
| Mar 31, 2026 | -45.32 Mn |
| Mar 31, 2026 | -45.32 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Sep 30, 2025 | -42.27 Mn |
| Sep 30, 2025 | -42.27 Mn |
| Jun 30, 2025 | -39.83 Mn |
| Jun 30, 2025 | -39.83 Mn |
| Mar 31, 2025 | -42.02 Mn |
| Mar 31, 2025 | -42.02 Mn |
| Dec 31, 2024 | -13.62 Mn |
| Dec 31, 2024 | -13.62 Mn |
| Sep 30, 2024 | -27.66 Mn |
| Sep 30, 2024 | -27.66 Mn |
| Jun 30, 2024 | -23.75 Mn |
| Jun 30, 2024 | -23.75 Mn |
| Mar 31, 2024 | -31.74 Mn |
| Mar 31, 2024 | -31.74 Mn |